Federico Lussana

Scopus Publications

Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement
Marco Frigeni, Alessandra Algarotti, Silvia Salmoiraghi, Clara Belotti, Martina Milani, Chiara Pavoni, Orietta Spinelli, Irene Gotuzzo, Alessandro Rambaldi, Federico Lussana
Annals of Hematology, 2026
Relapse of acute myeloid leukemia with CBFB::MYH11 fusion and KIT D816V mutation after allogeneic hematopoietic stem cell transplantation is uncommon and often associated with aggressive extramedullary spread and poor outcomes, particularly when the central nervous system is involved. We report a case of a 54‑year‑old man who developed extensive paravertebral, central nervous system, and multiorgan extramedullary relapse despite donor lymphocyte infusions and high‑dose chemotherapy. Avapritinib, a selective inhibitor of mutated KIT, was initiated as single‑agent therapy and resulted in rapid neurological improvement, complete metabolic response on positron emission tomography–computed tomography, and full molecular remission in peripheral blood. Due to temporary loss of off‑label access, avapritinib was discontinued, leading to a new extramedullary and central nervous system relapse. Remarkably, rechallenge with single‑agent avapritinib again induced molecular remission in both peripheral blood and cerebrospinal fluid, along with near‑complete metabolic response across all previously involved sites. The reproducibility of the response strongly supports a direct, target‑driven antileukemic effect. This case highlights the potential of avapritinib as an effective salvage therapy for KIT‑mutated acute myeloid leukemia with extramedullary and central nervous system involvement, including relapse after transplantation. The robust and repeated responses observed in this patient underscore the rationale the potential role of avapritinib as salvage therapy and support its investigation as a component of measurable residual disease-guided or post-transplant maintenance strategies.
BIALLELIC LOSS OF RB1 AND LPAR6 AT 13Q14 DRIVES KEY CELL CYCLE ABNORMALITIES IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Francesca Servoli
Haematologica, 2026
Introduction. Cell cycle dysregulation occurs in 70% of T-ALL/LBL cases and may result from diverse genetic alterations affecting CDKN2AB, CDKN1B, TP53, and/or RB1. RB1 maps to 13q14, the second most frequently deleted region in T-ALL/LBL (14%). These deletions often encompass DLEU1/2, long non-coding RNAs recurrently deleted in chronic lymphocytic leukemia, and/or RB1. Notably, an internal intron of RB1 harbors LPAR6, a G protein–coupled receptor that regulates cell proliferation and invasiveness, acting as either an oncogene or a tumor suppressor.Aim. Occurrence and functional impact of 13q14 deletions affecting RB1 and LPAR6.Methods. SNP array was used to identify copy number alterations in a cohort of 319 T-ALL/LBLs. Genomic studies included CI-FISH (La Starza R, 2020), which provided the genetic classification of 282 cases according to the main genetic subgroups, targeted custom NGS, and Whole Genome Sequencing (WGS). Gene expression studies were conducted by Whole Transcriptome Expression array (Bardelli V, 2025) and quantitative RT-PCR. Drug Response Profiling (DRP) (Pagliaro L, SIE 2025) on 70 drugs provided additional ex vivo functional data for a selection of 19 typical T-ALL cases.Results. A focal biallelic deletion encompassing RB1 and LPAR6 (RB1–LPAR6bDEL) was detected in 18 of 319 cases (6%) and showed a significant association with a cortical immunophenotype and the TLX1 molecular subtype. This alteration frequently co-occurred with lesions affecting other cell cycle regulators (CDKN2A/B, CDKN1B, CCND2) in 94% of cases, as well as with NOTCH1/FBXW7 mutations (83%) and/or alterations in JAK/STAT pathway members (72%). WGS confirmed the biallelic deletion and identified an RCBTB2::LPAR6 fusion in the four cases defining the minimal common deleted region. Cases harboring the RB1–LPAR6bDEL displayed significant downregulation of RB1 and LPAR6 and concomitant upregulation of E2F1, E2F2, and E2F7, members of the E2F transcription factor family involved in cell cycle regulation and DNA replication/repair. GSEA and pathway analysis demonstrated significant enrichment of E2F1-related signatures and of gene sets involved in DNA replication, cell cycle progression, and DNA repair, together with enrichment for NOTCH and MYC target genes and activation of the Wnt signaling pathway. Finally, we observed that RB1–LPAR6bDEL T-ALLs exhibited higher ex vivo sensitivity to BCL2 inhibition, along with greater chemoresistance when compared to controls.Conclusions. The RB1–LPAR6bDEL in cortical TLX1-positive T-ALL/LBL functionally recapitulates the effect of pRB phosphorylation, resulting in E2F1, E2F2, and E2F3 accumulation and subsequent S-phase entry and cell proliferation. Regarding the haploinsufficiency of LPAR6, which resembles that observed in normal CD34-positive cells, and the identification of the RCBTB2::LPAR6 fusion, further studies are warranted to elucidate their potential leukemogenic roles and the therapeutic implications.
INTEGRATING NGS AND OPTICAL GENOME MAPPING TO IMPROVE GENOMIC CHARACTERIZATION OF ADULT BCR:ABL1-NEGATIVE B-ALL
Lia Bonamici
Haematologica, 2026
Introduction: Adult B-cell acute lymphoblastic leukemia (B-ALL) lacking the BCR:ABL1 rearrangement represents most of adult cases (70–80%) and shows marked genetic heterogeneity. This complexity makes comprehensive characterization challenging with conventional diagnostic techniques, often resulting in long turnaround times and many “not otherwise specified” (NOS) cases. High-throughput genomic technologies may enhance patient stratification, alignment with guidelines, and deepen understanding of the disease genomic landscape.Methods: Bone marrow and peripheral blood samples underwent clinical, morphological, and conventional cytogenetic evaluation at diagnosis. A targeted RNA-based NGS assay (FUSIONPlex™ ALL Panel), detecting known and novel fusions and sequence variants across 81 ALL-relevant genes, was applied to all cases. Samples remaining unclassified after NGS were further analyzed, when material was available, by Optical Genome Mapping (OGM), which enables high-resolution, genome-wide detection of structural variants, including deletions, insertions, balanced/unbalanced rearrangements, and copy number variations.Results: Seventy-five adult BCR:ABL1-negative B-ALL patients diagnosed between 2009 and 2025 in two Italian centers were retrospectively analyzed (median age 46, IQR 27–65). Standard cytogenetics classified 61/75 (81%) patients as B-ALL, NOS, with risk assessment based only on clinical features. NGS identified 68 clinically relevant alterations in 48/75 cases (64%), most frequently affecting FLT3, NRAS, and PAX5. Among B-ALL, NOS cases, 37 (58.7%) harbored classifying alterations, allowing refined stratification into BCR:ABL1-like, PAX5 P80R, PAX5 altered (provisional entities) and other rare subtypes. In 8 patients, only non-classifying variants were detected (Figure 1). Despite the limited cohort size, molecular reclassification showed improved prognostic discrimination for overall survival (p= 0.0059). OGM confirmed previously detected abnormalities and expanded genomic characterization in all analyzed cases, including those negative by other methods. Complex karyotypes (≥3 events) were resolved in 6/9 patients. OGM also revealed cryptic lesions such as KMT2A focal amplification with isochromosome 17, a rare t(8;14) (q24;q32) translocation involving CEBPD:IGH, and also classifying alterations: the UBTF:ATXN7L3/PAN3, CDX2 (“CDX2/UBTF”) and a rare ZNF384 rearrangement.Conclusions: These findings support integrating NGS and OGM for improved genomic characterization of adult BCR:ABL1-negative B-ALL. NGS efficiently detects sequence-level variants, while OGM uncovers all kinds of structural alterations, providing a genome-wide view valuable for complex and atypical cases. This combined approach refines molecular stratification and disease characterization and may facilitate the identification of novel biomarkers and therapeutic targets. Validation in larger cohorts will confirm its clinical relevance and promote routine adoption
Acute Hemolytic Anemia Following Rasburicase in a Very Late Post-Transplant Relapse of Acute Myeloid Leukemia
Gianluca Cavallaro, Federico Lussana, Marco Frigeni, Maria Caterina Micò, Alessandra Algarotti, Anna Grassi, Orietta Spinelli, Chiara Pavoni, Elena Oldani, Alessandro Rambaldi
Mediterranean Journal of Hematology and Infectious Diseases, 2026
Disease relapse is the first cause of death after allogeneic stem cell transplant, and it commonly occurs within the first 2 years after transplant. We describe the case of a patient with a very late post-transplant relapse of AML, whose therapy was complicated by an acute hemolytic anemia.
The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis
Maria Chiara Finazzi, Silvia Salmoiraghi, Francesca Valsecchi, Chiara Pavoni, Clara Belotti, Anna Grassi, Alessandra Algarotti, Federico Lussana, Benedetta Rambaldi, Giuliana Rizzuto, Gianluca Cavallaro, Annalisa Condorelli, Marta Bellini, Orietta Spinelli, Alessandro Rambaldi
Blood Cancer Journal, 2025
Defining prognosis in myelofibrosis (MF) is of particular clinical relevance since survival may be highly heterogeneous, ranging from years to a few months. The biological landscape knowledge of MF has evolved in recent years, with the discovery of additional mutations in the myeloid-related genes beyond driver mutations. Mutations in ASXL1, EZH2, SRSF2, IDH1/2 and U2AF2 genes are defined as high-molecular risk mutations (HMR) [ 1 , 2 ], and their presence has been associated with poorer survival. Consequently, the presence of HMR mutations has been incorporated into various prognostic scores and helps in defining prognosis, driving therapeutic strategies.
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
Federico Lussana, Chiara F. Magnani, Stefania Galimberti, Giuseppe Gritti, Giuseppe Gaipa, Daniela Belotti, Benedetta Cabiati, Sara Napolitano, Silvia Ferrari, Alex Moretti, Chiara Buracchi, Gian Maria Borleri, Benedetta Rambaldi, Giuliana Rizzuto, Anna Grassi, Muriel Paganessi, Cristian Meli, Sarah Tettamanti, Giulia Risca, Giulia Pais, Giulio Spinozzi, Fabrizio Benedicenti, Giovanni Cazzaniga, Chiara Capelli, Elisa Gotti, Martino Introna, Josée Golay, Eugenio Montini, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi
Blood Cancer Journal, 2025
Non-viral engineering can ease CAR-T cell production and reduce regulatory and cost requirements. We utilized Sleeping Beauty transposon to engineer donor-derived anti-CD19.CD28.OX40.CD3zeta T cells differentiated in cytokine-induced killer (CARCIK-CD19) for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT). We report the results of CARCIK-CD19 observed in 36 patients (4 children and 32 adults) treated according to the final recommended dose. Cytokine release syndrome of grade 2 or lower occurred in 15 patients, ICANS grade 2 in 1 patient, and late-onset peripheral neurotoxicity of grade 3 in 2 patients. GVHD never occurred after treatment with allogeneic CARCIK-CD19. Complete remission was achieved by 30 out of 36 patients (83.3%), with MRD negativity in 89% of responders. With a median follow-up of 2.2 years, the 1-year overall survival was 57.0%, and event-free survival was 32.0%. The median duration of response at 1 year was 38.6%. CAR-T cells expanded rapidly after infusion and remained detectable for over 2 years. Integration site analysis after infusion showed a high clonal diversity. These data demonstrated that SB-engineered CAR-T cells are safe and induce durable remission in heavily pretreated patients with BCP-ALL relapsed after alloHSCT. Trial registration: The phase 1/2 and phase II trials are registered at www.clinicaltrials.gov as NCT#03389035 and NCT#05252403.
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
Fabio Guolo, Luana Fianchi, Maria Paola Martelli, Federico Lussana, Francesco Grimaldi, Federica Pilo, Michela Rondoni, Carla Filì, Paola Minetto, Debora Capelli, Patrizia Chiusolo, Massimo Breccia, Sara Mastaglio, Massimo Bernardi, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Valentina Mancini, Anna Lisa Piccioni, Luca Maurillo, Nicola Stefano Fracchiolla, Raffaele Palmieri, Calogero Vetro, Cristina Papayannidis, Lorenzo Brunetti, Alessandra Sperotto, Federica Gigli, Patrizia Zappasodi, Antonino Mulé, Caterina Patti, Erika Borlenghi, Michelina Dargenio, Federica Lessi, Marco Cerrano, Daniela Cilloni, Alessandro Isidori, Monia Lunghi, Caterina Alati, Carmela Gurrieri, Carola Riva, Giovanni Marconi, Ivana Lotesoriere, Samuele Gatani, Anna Maria Scattolin, Manuela Caizzi, Salvatore Perrone, Atto Billio, Filippo Gherlinzoni, Francesco Mannelli, Michele Gottardi, Roberto Cairoli, Anna Candoni, Felicetto Ferrara, Livio Pagano, Roberto Massimo Lemoli, Adriano Venditti, Elisabetta Todisco
American Journal of Hematology, 2025
In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (allo‐HSCT), and the activity of CPX‐351 in specific s‐AML subgroups are unclear. To evaluate these aspects, a total of 513 s‐AML patients (median age 65.6 years, 19–79) treated with CPX‐351 were retrospectively analyzed. Complete remission (CR) rate after induction was 297/513 (58%), increasing to 340/513 (66%) after cycle 2. Among the 340 responding patients, 118 (34.7%), 137 (40.3%), and 85 (25%) received none, one, or two consolidation cycles of CPX‐351, respectively. Overall, 230/513 patients (48.8%) received allo‐HSCT. Median follow up was 23.66 months and median overall survival (OS) was 16.23 months. Patients with mutated NPM1 or with ELN 2017 favorable risk (p < 0.05) had a significantly longer OS (p < 0.05). In a landmark analysis, receiving allo‐HSCT was associated with a longer survival (Median OS not reached vs. 16.3 months for patients receiving or not receiving allo‐HSCT, p < 0.05). Completion of all allowed CPX‐351 cycles was beneficial only in patients not proceeding to transplant (p < 0.05), whereas in transplanted patients additional CPX‐351 cycles did not improve outcome. Our analysis suggests that also s‐AML patients with NPM1 mutations and those belonging to the ELN 2017 favorable risk category benefit from CPX‐351. In eligible patients, allo‐HSCT should be performed as soon as a CR is achieved, whereas patients not undergoing transplant benefit from a complete CPX‐351 schedule.
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
M. Delia, D. Lazzarotto, S. Imbergamo, F. Mosna, C. Papayannidis, C. Pasciolla, A. Mulè, N. Fracchiolla, M. Leoncin, M. I. Del Principe, M. Fumagalli, M. Olivi, F. Guolo, M. Lunghi, M. De Gobbi, F. Lussana, L. Santoro, L. Aprile, P. Zappasodi, M. Ciccone, F. Giglio, V. P. Gagliardi, M. Dargenio, A. Curti, M. Bonifacio, S. Chiaretti, P. Musto, R. Foà, A. Candoni
Hematological Oncology, 2025
The introduction of pediatric‐inspired chemotherapy protocols for acute lymphoblastic leukemia (ALL) in the setting of adult patients affected by lymphoblastic lymphoma (LL) has improved the results in terms of outcomes. Within the Campus ALL network, we retrospectively collected data on 50 LL‐patients from 23 hematology centers in Italy treated according to the GIMEMA LAL1913 protocol, with the aim of confirming the ALL results and of testing the effectiveness of an approach based on higher cumulative doses of the non‐myelosuppressive components such as steroids and pegylated asparaginase, in addition to earlier and more intensive central nervous system prophylaxis. After cycle 3 (high dose methotrexate and cytarabine, C3), the cumulative incidence (CI) of PET‐based complete response (CR) was of 83% (median time to response from protocol start: 3.7 months; CI95%: 3.1–4.2). With a median follow‐up of 27.5 months, the 2‐year overall survival (OS), disease free survival (DFS) ed event free survival rates were of 77%, 76% and 69%, respectively. The 2‐year CI of relapse was of 26%. Multivariable analysis identified ECOG ≥ 2 as an independent prognostic factor for OS (HR = 3.279; CI95% 1.035–10.389, p = 0.044) and DFS (HR = 13.00, ICI95%: 3.383–57.909, p < 0.001), respectively. No significant impact was observed for pegylated asparaginase dose (reduced and/or omitted versus (vs.) full doses), age (≥ 55 vs. < 55), stage (0–I vs. II–IV), CD1a (negativity vs. other than CD1a negativity), bone marrow involvement (absent vs. ≤ 20%), or allotransplantation. The results of this study show the appropriateness of the LAL1913 protocol for the management of LL patients. Survival outcomes reflect those expected, although this drug combination was never tested before in a real‐life setting. Taken together, these results suggest that LAL1913 might be considered as a reference protocol for the frontline treatment of adult LL patients.
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
Davide Lazzarotto, Anna Maria Testi, Matteo Fanin, Federico Mosna, Sabina Chiaretti, Cristina Papayannidis, Antonio Curti, Matteo Piccini, Nicola Fracchiolla, Monica Fumagalli, Patrizia Zappasodi, Silvia Imbergamo, Paola Minetto, Fabio Guolo, Federico Lussana, Marco Cerrano, Fabio Forghieri, Matteo Leoncin, Matteo Olivi, Monia Lunghi, Silvia Trappolini, Carla Mazzone, Marzia Defina, Lara Aprile, Crescenza Pasciolla, Maria Ciccone, Endri Mauro, Antonino Mulè, Francesco Grimaldi, Benedetta Cambò, Lidia Santoro, Mario Delia, Valentina Mancini, Alessandro Cignetti, Renato Fanin, Massimiliano Bonifacio, Michelina Dargenio, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Anna Candoni
Annals of Hematology, 2025
The adoption of pediatric-inspired regimens for the treatment of Ph-negative acute lymphoblastic leukemia (ALL) in adults has improved prognosis. However, the feasibility of these intensive regimens in older patients is limited, due to the increased incidence of therapy-related side effects, including those related to asparaginase. In this sub-analysis carried out by the Campus ALL network, 90 ALL patients aged 55 or more (median age 59 years) homogeneously treated in real-life according to the GIMEMA LAL1913 program, were analyzed to evaluate the feasibility and tolerability of pegaspargase (PEG-ASP) treatment. Among the 90 patients analyzed, 86 (96%) received PEG-ASP at least in one of the first two courses (C1-C2) of chemotherapy and were evaluated for toxicity and outcome. In detail, 51 patients received PEG-ASP in both courses and 35 in either C1 or C2. The most common adverse event was hepatic toxicity (HT), with 38% of patients experiencing any grade of HT at C1 (HT grade ≥ 3, 19%) and 23% at C2 (HT grade ≥ 3, 9%). Additionally, HT at C1 was the primary reason for withholding PEG-ASP at C2. Coagulopathy was the second most frequent toxicity (any grade of toxicity in 26% of patients at C1 and in 20% at C2). No deaths directly related to PEG-ASP therapy were reported. The CR rate after C1 and C3 was 94% and 93%, respectively. MRD negativity rate was 40% and 68%, respectively. The OS and DFS probability at 3 years was 54% and 47%, respectively. PEG-ASP administration in older ALL patients is feasible, but HT is a concern, being the major cause of PEG-ASP interruption. Therefore, a dose adjustment, according to age and concomitant comorbidities, is advisable to balance PEG-ASP efficacy with its toxicity.
Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance
Marianna Ponzo, Lorenzo Drufuca, Chiara Buracchi, Marco M Sindoni, Silvia Nucera, Cristina Bugarin, Ramona Bason, Grazisa Rossetti, Raoul Bonnal, Cristian Meli, Benedetta Rambaldi, Federico Lussana, Silvia Ferrari, Alex Moretti, Giuseppe Dastoli, Giulia Risca, Christian Pellegrino, Markus G Manz, Stefania Galimberti, Alessandro Rambaldi, Giuseppe Gaipa, Andrea Biondi, Massimiliano Pagani, Chiara F Magnani
Journal for Immunotherapy of Cancer, 2025
Background Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment remains incompletely understood. Methods We performed single-cell RNA sequencing and spectral flow cytometry-based analyses of bone marrow-resident immune cells from B-ALL patients before and after CAR T-cell treatment. Results We observed profound changes in the microenvironment in response to CAR T-cell-mediated inflammation, including an increase in myeloid cells. Significant induction of the interferon response, hypoxia, and TGF-β signaling was accompanied by expansion of myeloid-derived suppressor cells (MDSCs) and endogenous exhausted CD8+ T cells. PD-1 expression in endogenous T cells post-treatment was associated with a lack of durable response in the cohort of patients analyzed. Further, we revealed that HIF-1α, VEGF, and TGFBR2 are key players in the intercellular communication between CAR T cells and the immune niche, potentially driving widespread T-cell dysfunction. Infusion of anti-CD19 CAR T cells led to increased accumulation of human MDSCs, exacerbation of a hypoxic environment and T-cell exhaustion in hematopoietic stem/progenitor cell-humanized mice bearing a human tumor. Conclusions In conclusion, CAR T-cell-mediated myeloid activation is associated with pathways of immune dysregulation that may antagonize the effects of therapy.
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study
Gianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni, Francesca Valsecchi, Anna Grassi, Cristina Papayannidis, Marco Cerrano, Nicola Fracchiolla, Fabio Giglio, Michelina Dargenio, Monia Lunghi, Silvia Imbergamo, Maria Ilaria Del Principe, Silvia Trappolini, Monica Fumagalli, Patrizia Zappasodi, Prassede Salutari, Mario Delia, Crescenza Pasciolla, Federico Mosna, Barbara Scappini, Fabio Forghieri, Patrizia Chiusolo, Cristina Skert, Benedetta Cambò, Marzia Defina, Giuseppe Lanzarone, Endri Mauro, Massimiliano Bonifacio, Carla Mazzone, Lidia Santoro, Antonino Mulè, Valentina Mancini, Paola Minetto, Giorgia Battipaglia, Alessandro Cignetti, Lara Aprile, Sabina Chiaretti, Robin Foà, Anna Candoni, Federico Lussana
Bone Marrow Transplantation, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial
Elias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, Anna Torrent, José J Rifón, Vaibhav Agrawal, Mar Tormo, Ryan D Cassaday, Thomas Cluzeau, Françoise Huguet, Cristina Papayannidis, Jesús M Hernández-Rivas, Anita Rijneveld, Shaun Fleming, Vladan Vucinic, Boris Böll, Takayuki Ikezoe, Maher Abdul-Hay, Mary L Savoie, Andre C Schuh, Celine Berthon, Stefan Schwartz, Sabina Chiaretti, Junichiro Yuda, Takuya Miyazaki, José González-Campos, Yuqi Chen, Hansen Wong, Jessica Choudhry, Gerhard Zugmaier, Erin Guest, Paul Gordon, Hagop Kantarjian
Lancet Haematology, 2025
Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06
Gianluca Cavallaro, Silvia Salmoiraghi, Roberta Cavagna, Chiara Pavoni, Clara Belotti, Martina Milani, Elena Oldani, Marco Frigeni, Tamara Intermesoli, Anna Grassi, Renato Bassan, Orietta Spinelli, Alessandro Rambaldi, Federico Lussana
Leukemia Research, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study
Renato Bassan, Sabina Chiaretti, Irene Della Starza, Alessandra Santoro, Orietta Spinelli, Manuela Tosi, Loredana Elia, Deborah Cardinali, Maria Stefania De Propris, Matteo Piccini, Federico Lussana, Mario Annunziata, Patrizia Chiusolo, Patrizia Zappasodi, Erika Borlenghi, Matteo Leoncin, Catello Califano, Monica Bocchia, Francesco Di Raimondo, Francesco Grimaldi, Mario Tiribelli, Anna Candoni, Albana Lico, Ernesta Audisio, Monia Lunghi, Anna Maria Mianulli, Mariangela Di Trani, Valentina Arena, Monica Messina, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà
Blood, 2025
Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda
C. Cattaneo, M. Bernardi, N. Fracchiolla, C. Pagani, F. Gigli, C. Basilico, L. Masina, E. Borlenghi, A. Bruno, G. Gela, G. Rossi, A. Tucci, D. Bertoli, F. Lussana, E. Todisco
Hematological Oncology, 2025
CMV Reactivations During and After Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Edoardo Olivari
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
Davide Lazzarotto, Marco Cerrano, Cristina Papayannidis, Sabina Chiaretti, Federico Mosna, Nicola Fracchiolla, Patrizia Zappasodi, Silvia Imbergamo, Maria Ilaria Del Principe, Monia Lunghi, Federico Lussana, Matteo Piccini, Monica Fumagalli, Michelina Dargenio, Prassede Salutari, Fabio Forghieri, Teresa Giulia Da Molin, Massimiliano Bonifacio, Matteo Olivi, Fabio Giglio, Silvia Trappolini, Matteo Leoncin, Antonino Mule, Mario Delia, Crescenza Pasciolla, Francesco Grimaldi, Benedetta Cambo, Lidia Santoro, Fabio Guolo, Paola Minetto, Marzia Defina, Patrizia Chiusolo, Matteo Fanin, Endri Mauro, Lara Aprile, Carla Mazzone, Fabio Trastulli, Maria Ciccone, Marco De Gobbi, Alessandro Cignetti, Eleonora De Bellis, Valentina Mancini, Alfonso Piciocchi, Marco Vignetti, Giovanni Marsili, Irene Della Starza, Renato Fanin, Mario Luppi, Felicetto Ferrara, Giovanni Pizzolo, Renato Bassan, Robin Foa, Anna Candoni
Haematologica, 2025
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
Giuseppe Gritti, Silvia Ferrari, Federico Lussana, Anna Maria Barbui, Francesco Landi, Monica Rondi, Alessandro Putelli, Francesco Ballardini, Giulia Quaresmini, Muriel Paganessi, Chiara Pavoni, Arianna Ghirardi, Elisa Gotti, Chiara Capelli, Josée Golay, Martino Introna, Alessandro Rambaldi
Blood Cancer Journal, 2024
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience
Marta Castelli, Maria Caterina Micò, Anna Grassi, Alessandra Algarotti, Federico Lussana, Maria Chiara Finazzi, Benedetta Rambaldi, Chiara Pavoni, Giuliana Rizzuto, Paola Tebaldi, Francesca Vendemini, Marta Verna, Sonia Bonanomi, Andrea Biondi, Adriana Balduzzi, Alessandro Rambaldi, Giacomo Gotti
Bone Marrow Transplantation, 2024
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study
Annalisa Condorelli, Marco Frigeni, Giulia Quaresmini, Silvia Salmoiraghi, Chiara Pavoni, Anna Grassi, Matteo Raviglione, Alessia Civini, Alessandro Putelli, Federico Lussana, Maria Chiara Finazzi, Alessandra Algarotti, Maria Caterina Micò, Orietta Spinelli, Alessandro Rambaldi
Leukemia Research, 2024
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation
Maria Chiara Finazzi, Alessandra Weber, Chiara Pavoni, Anna Grassi, Maria Caterina Micò, Alessandra Algarotti, Federico Lussana, Alessandro Rambaldi
Bone Marrow Transplantation, 2024
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda
Giuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, Federico Lussana, Massimo Bernardi, Claudia Basilico, Alfredo Molteni, Ivana Lotesoriere, Mauro Turrini, Marco Frigeni, Monica Fumagalli, Paola Cozzi, Federica Gigli, Chiara Cattaneo, Nicola Stefano Fracchiolla, Marta Riva, Gianluca Martini, Valentina Mancini, Roberto Cairoli, Elisabetta Todisco
Cancers, 2024
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study
Darina Ocadlikova, Federico Lussana, Nicola Fracchiolla, Massimiliano Bonifacio, Lidia Santoro, Mario Delia, Sabina Chiaretti, Crescenza Pasciolla, Alessandro Cignetti, Fabio Forghieri, Francesco Grimaldi, Giulia Corradi, Letizia Zannoni, Stefania De Propris, Gian Maria Borleri, Ilaria Tanasi, Jayakumar Vadakekolathu, Sergio Rutella, Anna Rita Guarini, Robin Foà, Antonio Curti, and
British Journal of Haematology, 2023
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "old-fashioned" Drug be Effective?
Marta Riva, Alessandro Bosi, Lorenzo Rizzo, Federico Mazzon, Silvia Ferrari, Federico Lussana, Lorenza Borin, Andrea Castelli, Roberto Cairoli, Wilma Barcellini, Alfredo Molteni, Bruno Fattizzo
Hemasphere, 2023
Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Giebel, Myriam Labopin, Mohamed Houhou, Denis Caillot, Jürgen Finke, Didier Blaise, Nathalie Fegueux, Mark Ethell, Jan J. Cornelissen, Edouard Forcade, Ibrahim Yakoub-Agha, Federico Lussana, Johan Maertens, Jean Henri Bourhis, Pavel Jindra, Norbert Claude Gorin, Arnon Nagler, Mohamad Mohty
Bone Marrow Transplantation, 2023
Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
Federico Lussana, Gianluca Cavallaro, Pantaleo De Simone, Alessandro Rambaldi
Cancers, 2023
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report
Sabina Chiaretti, Massimiliano Bonifacio, Roberta Agrippino, Fabio Giglio, Mario Annunziata, Antonio Curti, Maria Ilaria Del Principe, Prassede Salutari, Mariarita Sciumè, Mario Delia, Marco Armenio, Valentina Mancini, Antonino Mulè, Francesco Grimaldi, Giovanna Rege-Cambrin, Lidia Santoro, Federico Lussana, Patrizia Chiusolo, Crescenza Pasciolla, Anna Maria Scattolin, Marco Cerrano, Maria Ciccone, Marzia Defina, Fabio Forghieri, Carla Mazzone, Matteo Piccini, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà
Haematologica, 2022
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Massimiliano Bonifacio, Cristina Papayannidis, Federico Lussana, Nicola Fracchiolla, Mario Annunziata, Simona Sica, Mario Delia, Robin Foà, Giovanni Pizzolo, Sabina Chiaretti
Frontiers in Oncology, 2022
Clinical significance of chromatin-spliceosome acute myeloid leukemia: A report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
Chiara Caprioli, Federico Lussana, Silvia Salmoiraghi, Roberta Cavagna, Ksenija Buklijas, Lara Elidi, Pamela Zanghi', Anna Michelato, Federica Delaini, Elena Oldani, Tamara Intermesoli, Anna Grassi, Giacomo Gianfaldoni, Francesco Mannelli, Dario Ferrero, Ernesta Audisio, Elisabetta Terruzzi, Lorella De Paoli, Chiara Cattaneo, Erika Borlenghi, Irene Cavattoni, Monica Tajana, Anna Maria Scattolin, Daniele Mattei, Paolo Corradini, Leonardo Campiotti, Fabio Ciceri, Massimo Bernardi, Elisabetta Todisco, Agostino Cortelezzi, Brunangelo Falini, Chiara Pavoni, Renato Bassan, Orietta Spinelli, Alessandro Rambaldi
Haematologica, 2021
Skip pattern approach toward the early access of innovative anticancer drugs
G. Apolone, A. Ardizzoni, A. Biondi, A. Bortolami, C. Cardone, C.M. Ciniselli, P. Conte, C. Crippa, F. de Braud, M. Duca, S. Gori, G. Gritti, A. Inno, R. Luksch, F. Lussana, M. Maio, G. Pasello, F. Perrone, A. Rambaldi, G. Rossi, D. Signorelli, G. Soverini, M. Valente, P. Verderio, G. Buzzetti
ESMO Open, 2021
Mrd‐based therapeutic decisions in genetically defined subsets of adolescents and young adult philadelphia‐negative all
Manuela Tosi, Orietta Spinelli, Matteo Leoncin, Roberta Cavagna, Chiara Pavoni, Federico Lussana, Tamara Intermesoli, Luca Frison, Giulia Perali, Francesca Carobolante, Piera Viero, Cristina Skert, Alessandro Rambaldi, Renato Bassan
Cancers, 2021
Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies
Federico Lussana, Giuseppe Gritti, Alessandro Rambaldi
Journal of Clinical Oncology, 2021
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies
Silvia Ferrari, Chiara Caprioli, Alessandra Weber, Alessandro Rambaldi, Federico Lussana
Leukemia and Lymphoma, 2021
Concurrent diagnosis of acute myeloid leukemia and symptomatic covid-19 infection: A case report successfully treated with azacitidine-venetoclax combination
Daniela Taurino, Marco Frigeni, Anna Grassi, Gianluca Cavallaro, Silvia Salmoiraghi, Orietta Spinelli, Alessandro Rambaldi, Federico Lussana
Mediterranean Journal of Hematology and Infectious Diseases, 2021
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study
Anna Candoni, Davide Lazzarotto, Felicetto Ferrara, Antonio Curti, Federico Lussana, Cristina Papayannidis, Maria Ilaria Del Principe, Massimiliano Bonifacio, Federico Mosna, Mario Delia, Paola Minetto, Michele Gottardi, Nicola Fracchiolla, Valentina Mancini, Fabio Forghieri, Patrizia Zappasodi, Marco Cerrano, Antonella Vitale, Ernesta Audisio, Silvia Trappolini, Claudio Romani, Marzia Defina, Silvia Imbergamo, Nadia Ciccone, Lidia Santoro, Benedetta Cambò, Salvatore Iaccarino, Michela Dargenio, Lara Aprile, Sabina Chiaretti, Renato Fanin, Giovanni Pizzolo, Roberto Foà
American Journal of Hematology, 2020
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri, Grazia Fazio, Silvia Zaninelli, Sarah Tettamanti, Stefania Cesana, Valentina Colombo, Michele Quaroni, Giovanni Cazzaniga, Attilio Rovelli, Ettore Biagi, Stefania Galimberti, Andrea Calabria, Fabrizio Benedicenti, Eugenio Montini, Silvia Ferrari, Martino Introna, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi
Journal of Clinical Investigation, 2020
National Italian Delphi panel consensus: Which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
Federico Lussana, Paola Minetto, Felicetto Ferrara, Sabina Chiaretti, Giorgina Specchia, Renato Bassan
BMC Cancer, 2020
High throughput molecular characterization of normal karyotype acute myeloid leukemia in the context of the prospective trial 02/06 of the northern italy leukemia group (NILG)
Silvia Salmoiraghi, Roberta Cavagna, Pamela Zanghì, Chiara Pavoni, Anna Michelato, Ksenija Buklijas, Lara Elidi, Tamara Intermesoli, Federico Lussana, Elena Oldani, Chiara Caprioli, Paola Stefanoni, Giacomo Gianfaldoni, Ernesta Audisio, Elisabetta Terruzzi, Lorella De Paoli, Erika Borlenghi, Irene Cavattoni, Daniele Mattei, Annamaria Scattolin, Monica Tajana, Fabio Ciceri, Elisabetta Todisco, Leonardo Campiotti, Paolo Corradini, Nicola Fracchiolla, Renato Bassan, Alessandro Rambaldi, Orietta Spinelli
Cancers, 2020
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study
, Gualtiero Palareti, Cristina Legnani, Emilia Antonucci, Benilde Cosmi, Daniela Poli, Sophie Testa, Alberto Tosetto, Walter Ageno, Anna Falanga, Piera Maria Ferrini, Vittorio Pengo, Paolo Prandoni
Internal and Emergency Medicine, 2020
Evaluation of platelet function in essential thrombocythemia under different analytical conditions
Federico Lussana, Eti Alessandra Femia, Mariateresa Pugliano, Gianmarco Podda, Cristina Razzari, Norma Maugeri, Anna Lecchi, Sabrina Caberlon, Giancarla Gerli, Marco Cattaneo
Platelets, 2020
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO)
Anna Candoni, Alessandro Rambaldi, Renato Fanin, Andrea Velardi, William Arcese, Fabio Ciceri, Davide Lazzarotto, Federico Lussana, Jacopo Olivieri, Giovanni Grillo, Matteo Parma, Benedetto Bruno, Federica Sora, Paolo Bernasconi, Riccardo Saccardi, Robin Foà, Mariarosa Sessa, Paola Bresciani, Fabio Giglio, Alessandra Picardi, Alessandro Busca, Simona Sica, Katia Perruccio, Elisa Zucchetti, Elisa Diral, Anna Paola Iori, Anna Amelia Colombo, Stefano Tringali, Stella Santarone, Giuseppe Irrera, Stefano Mancini, Francesco Zallio, Michele Malagola, Francesco Albano, Angelo Michele Carella, Attilio Olivieri, Cristina Tecchio, Alida Dominietto, Adriana Vacca, Roberto Sorasio, Enrico Orciuolo, Antonio Maria Risitano, Salvatore Leotta, Agostino Cortelezzi, Sonia Mammoliti, Elena Oldani, Francesca Bonifazi
Biology of Blood and Marrow Transplantation, 2019
Molecular detection of minimal residual disease before allogeneic stem cell transplantation predicts a high incidence of early relapse in adult patients with NPM1 positive acute myeloid leukemia
Federico Lussana, Chiara Caprioli, Paola Stefanoni, Chiara Pavoni, Orietta Spinelli, Ksenija Buklijas, Anna Michelato, GianMaria Borleri, Alessandra Algarotti, Caterina Micò, Anna Grassi, Tamara Intermesoli, Alessandro Rambaldi
Cancers, 2019
Thrombosis prophylaxis in pediatric liver transplantation: A systematic review
Mirco Nacoti, Giulia Maria Ruggeri, Giovanna Colombo, Ezio Bonanomi, Federico Lussana
World Journal of Hepatology, 2018
Heparin-like effect resistant to protamine in a child with haemorrhagic shock. Do we need heparinase?
Mirco Nacoti, Diego Cantù, Daniele Bonacina, Federico Lussana, Ezio Bonanomi, et al.
Blood Transfusion, 2018
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana, Marco Cattaneo, Alessandro Rambaldi, Alessandro Squizzato
American Journal of Hematology, 2018
Mechanisms of resistance to targeted therapies in chronic myeloid leukemia
Federico Lussana, Tamara Intermesoli, Paola Stefanoni, Alessandro Rambaldi
Handbook of Experimental Pharmacology, 2018
Inflammation and myeloproliferative neoplasms
Federico Lussana, Alessandro Rambaldi
Journal of Autoimmunity, 2017
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
Martino Introna, Federico Lussana, Alessandra Algarotti, Elisa Gotti, Rut Valgardsdottir, Caterina Micò, Anna Grassi, Chiara Pavoni, Maria Luisa Ferrari, Federica Delaini, Elisabetta Todisco, Irene Cavattoni, Sara Deola, Ettore Biagi, Adriana Balduzzi, Attilio Rovelli, Matteo Parma, Sara Napolitano, Giusy Sgroi, Emanuela Marrocco, Paolo Perseghin, Daniela Belotti, Benedetta Cabiati, Giuseppe Gaipa, Josée Golay, Andrea Biondi, Alessandro Rambaldi
Biology of Blood and Marrow Transplantation, 2017
Tregs: Hype or hope for allogeneic hematopoietic stem cell transplantation?
F Lussana, M Di Ianni, A Rambaldi
Bone Marrow Transplantation, 2017
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies
Maria Chiara Finazzi, Federico Lussana, Silvia Salmoiraghi, Orietta Spinelli, Alessandro Rambaldi
Expert Review of Hematology, 2017
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Federico Lussana, Alessandra Carobbio, Silvia Salmoiraghi, Paola Guglielmelli, Alessandro Maria Vannucchi, Barbara Bottazzi, Roberto Leone, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi
Journal of Hematology and Oncology, 2017
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome
Federico Lussana, Tamara Intermesoli, Francesca Gianni, Cristina Boschini, Arianna Masciulli, Orietta Spinelli, Elena Oldani, Manuela Tosi, Anna Grassi, Margherita Parolini, Ernesta Audisio, Chiara Cattaneo, Roberto Raimondi, Emanuele Angelucci, Irene Maria Cavattoni, Anna Maria Scattolin, Agostino Cortelezzi, Francesco Mannelli, Fabio Ciceri, Daniele Mattei, Erika Borlenghi, Elisabetta Terruzzi, Claudio Romani, Renato Bassan, Alessandro Rambaldi
Biology of Blood and Marrow Transplantation, 2016
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review
Alessandro Squizzato, Federico Lussana, Walter Ageno, Marco Cattaneo
Internal and Emergency Medicine, 2016
Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis
Maddalena L. Zighetti, Gessica Fontana, Federico Lussana, Valentina Chiesa, Aglaia Vignoli, Maria Paola Canevini, Marco Cattaneo
Epilepsia, 2015
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty
Federico Lussana, Marco Cattaneo, Alessandro Squizzato
Thrombosis and Haemostasis, 2015
Effect of prasugrel in patients with asthma: Results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study
F. Lussana, F. Di Marco, S. Terraneo, M. Parati, C. Razzari, M. Scavone, E.A. Femia, A. Moro, S. Centanni, M. Cattaneo
Journal of Thrombosis and Haemostasis, 2015
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
Federico Lussana, Alessandra Carobbio, Maria L. Randi, Chiara Elena, Elisa Rumi, Guido Finazzi, Irene Bertozzi, Lisa Pieri, Marco Ruggeri, Francesca Palandri, Nicola Polverelli, Elena Elli, Alessia Tieghi, Alessandra Iurlo, Marco Ruella, Mario Cazzola, Alessandro Rambaldi, Alessandro M. Vannucchi, Tiziano Barbui
British Journal of Haematology, 2014
A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty
Federico Lussana, Alessandro Squizzato, Eleonora Tamborini Permunian, Marco Cattaneo
Thrombosis Research, 2014
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: A report from the MPN subcommittee of the chronic malignancies working party of the European group for blood and marrow transplantation
F. Lussana, A. Rambaldi, M. C. Finazzi, A. van Biezen, M. Scholten, E. Oldani, A. Carobbio, S. Iacobelli, J. Finke, A. Nagler, L. Volin, T. Lamy, R. Arnold, M. Mohty, M. Michallet, T. de Witte, E. Olavarria, N. Kroger
Haematologica, 2014
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia
Maria Luigia Randi, Irene Bertozzi, Elisa Rumi, Chiara Elena, Guido Finazzi, Nicola Vianelli, Nicola Polverelli, Marco Ruggeri, Alessandro Maria Vannucchi, Elisabetta Antonioli, Federico Lussana, Alessia Tieghi, Alessandra Iurlo, Elena Elli, Marco Ruella, Fabrizio Fabris, Mario Cazzola, Tiziano Barbui
American Journal of Hematology, 2014
Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia
Federico Lussana, Alessandro Rambaldi
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia
Federico Lussana, Silvia Betti, Armando D’Angelo, Valerio De Stefano, Sandra Fedi, Paola Ferrazzi, Cristina Legnani, Rossella Marcucci, Gualtiero Palareti, Lidia L. Rota, Francesca Sampietro, Alessandro Squizzato, Domenico Prisco, Marco Cattaneo
Thrombosis Research, 2013
Recommendations for the standardization of light transmission aggregometry: A consensus of the working party from the platelet physiology subcommittee of SSC/ISTH
M. Cattaneo, C. Cerletti, P. Harrison, C.P.M. Hayward, D. Kenny, D. Nugent, P. Nurden, A.K. Rao, A.H. Schmaier, S.P. Watson, F. Lussana, M.T. Pugliano, A.D. Michelson
Journal of Thrombosis and Haemostasis, 2013
Prevalence of factor V leiden and G20210A prothrombin mutation in the Dutch famine birth cohort: A possible survival advantage?
Susanne R. de Rooij, Marjolein Veenendaal, Cristina Razzari, Gessica Fontana, Elena M. Faioni, Rebecca C. Painter, Saskia Middeldorp, Marco Cattaneo, Tessa J. Roseboom, Federico Lussana
Thrombosis and Haemostasis, 2012
The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation
M. Nacoti, S. Cazzaniga, F. Lorusso, L. Naldi, P. Brambillasca, A. Benigni, V. Corno, M. Colledan, E. Bonanomi, S. Vedovati, S. Buoro, A. Falanga, F. Lussana, T. Barbui, V. Sonzogni
Pediatric Transplantation, 2012
Pregnancy-related venous thromboembolism: Risk and the effect of thromboprophylaxis
Federico Lussana, Michiel Coppens, Marco Cattaneo, Saskia Middeldorp
Thrombosis Research, 2012
Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia
Norma Maugeri, Simona Malato, Eti A. Femia, Mariateresa Pugliano, Lara Campana, Francesca Lunghi, Patrizia Rovere-Querini, Federico Lussana, GianMarco Podda, Marco Cattaneo, Fabio Ciceri, Angelo A. Manfredi
Blood, 2011
Can plasma levels of N-terminal pro-brain natriuretic peptide be useful in predicting the risk of developing chronic pulmonary hypertension in patients with pulmonary embolism?
Federico Lussana, Gian Marco Podda, Marco Cattaneo
Internal and Emergency Medicine, 2009
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana, Sabrina Caberlon, Chiara Pagani, Pieter W. Kamphuisen, Harry R. Büller, Marco Cattaneo
Thrombosis Research, 2009
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)
Alfonso Iorio, Walter Ageno, Benilde Cosmi, Davide Imberti, Federico Lussana, Sergio Siragusa, Daniela Tormene, Alberto Tosetto, Marco Cattaneo
Thrombosis Research, 2009
Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)
Federico Lussana, Francesco Dentali, Rosanna Abbate, Ernesto d'Aloja, Armando D'Angelo, Valerio De Stefano, Elena M. Faioni, Elvira Grandone, Cristina Legnani, Ida Martinelli, Paolo Simioni, Daniela Tormene
Thrombosis Research, 2009
Prenatal exposure to the Dutch famine is associated with a preference for fatty foods and a more atherogenic lipid profile
Federico Lussana, Rebecca C Painter, Marga C Ocke, Harry R Buller, Patrick M Bossuyt, Tessa J Roseboom
American Journal of Clinical Nutrition, 2008
Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: A meta-analysis
Francesco Dentali, Monica Gianni, Federico Lussana, Alessandro Squizzato, Marco Cattaneo, Walter Ageno
British Journal of Haematology, 2008
Usefulness of PFA-100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: Comparison with the bleeding time
G.M. PODDA, P. BUCCIARELLI, F. LUSSANA, A. LECCHI, M. CATTANEO
Journal of Thrombosis and Haemostasis, 2007
Venous thrombosis at unusual sites and the role of thrombophilia
Federico Lussana, Francesco Dentali, Walter Ageno, Pieter Kamphuisen
Seminars in Thrombosis and Hemostasis, 2007
Abnormalities of homocysteine and B vitamins in the nephrotic syndrome
Gian Marco Podda, Federico Lussana, Gabriella Moroni, Elena M. Faioni, Rossana Lombardi, Gessica Fontana, Claudio Ponticelli, Claudio Maioli, Marco Cattaneo
Thrombosis Research, 2007
A rare case of autoimmune haemolytic anaemia due to warm IgA autoantibodies with reticulocytopenia
F. Lussana, S. Caberlon, S. Altomare, M. Lanfredini, M. Cattaneo
Internal and Emergency Medicine, 2007
Platelet aggregation studies: Autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count
M. Cattaneo, A. Lecchi, M. L. Zighetti, F. Lussana
Haematologica, 2007
New approaches for measuring coagulation
T. W. BARROWCLIFFE, M. CATTANEO, G. M. PODDA, P. BUCCIARELLI, F. LUSSANA, A. LECCHI, C. H. TOH, H. C. HEMKER, S. BÉGUIN, J. INGERSLEV, B. SØRENSEN
Haemophilia, 2006
Association of estrogen receptor-α gene polymorphisms with venous thrombosis
Haematologica, 2006
Association of factor V deficiency with factor V HR2
Haematologica, 2004
Blood levels of homocysteine, folate, vitamin B6 and B 12 in women using oral contraceptives compared to non-users
Federico Lussana, Maddalena L Zighetti, Paolo Bucciarelli, Massimo Cugno, Marco Cattaneo
Thrombosis Research, 2003
Hyperhomocysteinemia and cardiovascular aging
Marco Cattaneo, Federico Lussana
Advances in Cell Aging and Gerontology, 2002
Changes in health and disease of the metalloprotease that cleaves von Willebrand factor
Pier Mannuccio Mannucci, Maria Teresa Canciani, Ileana Forza, Federico Lussana, Antonella Lattuada, Edoardo Rossi
Blood, 2001

Federico Lussana

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications